Diligence and Commercialization. 3.1 Licensee agrees to invest [*] toward the further development of Licensed Products in the field of cancer therapy within eighteen (18) months after the execution date of the Agreement. If Licensee fails to make the required investment, and does not remedy that failure within sixty (60) days after written notice to Licensee, MCGRI, as its sole and exclusive remedy for such failure, may convert Licensee’s right and license in the Field of Use for oncology to non-exclusive.
Appears in 3 contracts
Samples: Stock Subscription Agreement (Newlink Genetics Corp), Stock Subscription Agreement (Newlink Genetics Corp), License Agreement (Newlink Genetics Corp)
Diligence and Commercialization. 3.1 Licensee agrees to invest [*] $500,000 toward the further development of Licensed Products in the field of cancer therapy within eighteen (18) months after the execution date of the Agreement. If Licensee fails to make the required investment, and does not remedy that failure within sixty (60) days after written notice to Licensee, MCGRI, as its sole and exclusive remedy for such failure, may convert Licensee’s right and license in the Field of Use for oncology to non-exclusive.
Appears in 1 contract
Samples: Stock Subscription Agreement (Newlink Genetics Corp)